<?xml version="1.0" encoding="UTF-8"?>
<ref id="B99-pharmaceuticals-12-00060">
 <label>99.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kamiyama</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Soma</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Hidano</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Watanabe</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Umekita</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Fukuda</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Noguchi</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Gendo</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Ozaki</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Sonoda</surname>
    <given-names>A.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice</article-title>
  <source>Antiviral Res.</source>
  <year>2017</year>
  <volume>146</volume>
  <fpage>1</fpage>
  <lpage>11</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.08.007</pub-id>
  <pub-id pub-id-type="pmid">28818572</pub-id>
 </element-citation>
</ref>
